Want to see SE:INIT full AI Analyst Report?

Initiator Pharma A/S (INIT) Price & Analysis

0 Followers

INIT Stock Chart & Stats

kr2.29

kr0.25(10.92%)

At close: Jul 27 4:00 PM EDT

kr2.29

kr0.25(10.92%)

Day’s Range― - ―

52-Week Rangekr2.14 - kr4.07

Previous CloseN/A

Volume40.71K

Average Volume (3M)133.41K

Market Cap

kr160.86M

Enterprise Valuekr173.87

Total Cash (Recent Filing)kr17.10M

Total Debt (Recent Filing)kr9.69M

Price to Earnings (P/E)―

Beta0.78

Next Earnings

Nov 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding68,452,890

10 Day Avg. Volume157,519

30 Day Avg. Volume133,406

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)4.31

Price to Sales (P/S)0.00

P/FCF Ratio-7.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.63

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused Therapeutic StrategyA concentrated therapeutic focus can help direct limited resources toward a clearly defined medical need, simplify development priorities, and build specialized expertise in erectile dysfunction and related reproductive-health markets.

Lead Asset Targets Unmet NeedTargeting patients who may respond inadequately to current PDE5 inhibitors provides a clinically meaningful differentiation opportunity. If development succeeds, this positioning could support adoption beyond the standard treatment population.

Small-Molecule Development PlatformSmall-molecule drug development can offer established formulation and manufacturing pathways compared with more complex biologics. This may support scalable commercialization and potentially broaden access if clinical efficacy and safety are demonstrated.

Bears Say

Pre-Revenue Business ModelThe absence of commercial revenue means the company has not yet demonstrated product-market traction or recurring operating cash inflows. Funding requirements will therefore remain closely tied to clinical progress and future commercialization.

Widening Losses And Cash BurnDeepening losses alongside substantial cash outflows indicate that development activities are consuming significant capital without offsetting revenue. Continued burn can shorten the funding runway and increase dependence on additional financing.

Deteriorating Balance SheetHigher debt and sharply lower equity reduce financial flexibility for a loss-making clinical-stage company. The weaker capital base increases refinancing and potential dilution risk, particularly if development milestones require substantial new funding.

INIT FAQ

What was Initiator Pharma A/S’s price range in the past 12 months?

Initiator Pharma A/S lowest stock price was kr2.14 and its highest was kr4.07 in the past 12 months.

What is Initiator Pharma A/S’s market cap?

Initiator Pharma A/S’s market cap is kr160.86M.

When is Initiator Pharma A/S’s upcoming earnings report date?

Initiator Pharma A/S’s upcoming earnings report date is Nov 20, 2026 which is in 83 days.

How were Initiator Pharma A/S’s earnings last quarter?

Initiator Pharma A/S released its earnings results on Aug 21, 2026. The company reported -kr0.202 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Initiator Pharma A/S overvalued?

According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Initiator Pharma A/S pay dividends?

Initiator Pharma A/S does not currently pay dividends.

What is Initiator Pharma A/S’s EPS estimate?

Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Initiator Pharma A/S have?

Initiator Pharma A/S has 68,452,890 shares outstanding.

What happened to Initiator Pharma A/S’s price movement after its last earnings report?

Initiator Pharma A/S reported an EPS of -kr0.202 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.372%.

Which hedge fund is a major shareholder of Initiator Pharma A/S?

Currently, no hedge funds are holding shares in SE:INIT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Initiator Pharma A/S

Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.